Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moexipril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 15/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moexipril SCHEMBL3967866 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL28096307 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL30903896 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL9809013 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL29383460 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL14660386 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL40877 | 1.00 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL11268790 | 0.99 | ACE (0.97) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL683321 | 0.99 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL22175779 | 0.99 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050119311-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2005-06-02 | — | — | US | disclosed |
| US-4344949-A | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1982-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119311-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | ACE 1210/4885PDE3A 2985/4885ABCB11 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.